Navigation Links
MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs

    MEMOTEXT(R) Personalized Adherence Interventions Incorporated into
    First-of-its-Kind Study Funded by Microsoft HealthVault Be Well Fund

BETHESDA, MD, Jan. 13 /PRNewswire/ - MEMOTEXT announced today that Johns Hopkins University's Wilmer Eye Institute will conduct a clinical trial on patient adherence and clinical outcomes for people with glaucoma using technology developed by MEMOTEXT. The clinical trial, titled "The Impact of Automated Dosing Reminders on Medication Adherence Using HealthVault," is funded by a Microsoft(R) HealthVault(TM) Be Well Fund grant. The 14-month study, to be led by Michael V. Boland, M.D., Ph.D. of the Wilmer Eye Institute, will recruit 500 patients and use telephone calls and text messages in an effort to improve patient outcomes by improving medication adherence.

"We believe this new interface will significantly improve medication adherence in patients with glaucoma," says Amos Adler, President of MEMOTEXT. "It is an honor to collaborate on this special grant, and we are confident this trial will demonstrate that MEMOTEXT's technology-driven adherence solutions can make a significant difference in the lives of patients managing various conditions."

Studies have shown that medication non-adherence costs North America more than $100 billion and 125,000 lives every year. Medication non-adherence impacts all levels of health management, including treatment effectiveness and unnecessary hospitalizations, and almost six percent of all hospital admissions are due to failed patient adherence. Research also indicates that 70% of prescriptions are never consumed and 20% of all new drug prescriptions are never filled for the first time - with adherence rates as low as 10-20% for some disease states.

Approximately 40% of glaucoma patients have difficulty taking their eye drops on a regular basis, resulting in poor care despite an appropriate physician diagnosis and treatment plan. With the Internet and mobile phones so prevalent in patients' lives, they offer new ways to customize a patient adherence regimen. The results of this study should demonstrate MEMOTEXT program's usefulness for glaucoma, as well as the many other chronic diseases where adherence is important.

"Adherence to glaucoma therapy is one of the largest barriers we face in achieving therapeutic success," said glaucoma specialist Donald Budenz, M.D., M.P.H., of the Bascom Palmer Eye Institute in Miami. "We have numerous effective medications to treat this disease, but if patients don't use them, they're not effective. Providing real-time reminders to improve adherence to therapy will be a major step forward in the treatment of chronic diseases such as glaucoma."

The Be Well Fund is designed to stimulate not-for-profit research and development across a broad range of health disciplines that have the potential to significantly improve health and wellness outcomes by seeding innovative avenues of research and exploring the potential for disruptive improvements to health management enabled by re-use and sharing of data among people, families, caregivers, doctors and facilities.

"The Be Well Fund winners share our vision of using the Internet to empower people to fully engage in managing their health and improving health outcomes," said David Cerino, general manager of the Health Solutions Group at Microsoft Corp. "We're excited to help these organizations turn their ideas into reality and to expand the capabilities and services available through HealthVault."

Microsoft received nearly 200 proposals from leading academic and health research organizations across the United States, making it one of the most successful Microsoft Research RFPs in the company's history. Based on the strong interest, Microsoft increased award funding from $3 million to $4.5 million to help bring these proposals to market.

    About "The Impact of Automated Dosing Reminders on Medication Adherence
    using HealthVault" Trial

This clinical trial will be completed in 14 months and in three phases: software development, a clinical research study, and subsequent data analysis. 500 subjects will be recruited in the U.S. for the two-part study, which includes a cohort study to assess baseline adherence with glaucoma medications followed by a randomized, controlled trial of the adherence intervention. Approximately 100 subjects will be randomized to participate in the technology-based adherence intervention program. The results of the study will be presented in a peer-reviewed forum upon completion of the trial, which is expected to conclude in mid-2010.

About Glaucoma and Adherence

Glaucoma is the second leading cause of blindness and visual disability worldwide. It's estimated that 2.5 million people in the U.S. are affected by glaucoma, with another 10 million undiagnosed. By the year 2010, worldwide, the number is predicted to be 60 million. Currently, there is no cure for glaucoma. However, studies have shown that reducing the eye pressure with topical medical therapy, office laser or surgery can prevent occurrence or slow disease progression. The majority of patients diagnosed with glaucoma or ocular hypertension are managed initially with medications. However, despite the availability of effective topical therapies, non-adherence in patients with glaucoma is poor and has been reported between 37-59%.


MEMOTEXT is a specialized healthcare application service provider focused on providing medication adherence intervention solutions. With over 25 years of expertise in patient-stakeholder issues and the telecommunications industry, MEMOTEXT integrates behavior modification, patient education and live support into the everyday lives of patients. MEMOTEXT uses proven methodologies and customized solutions that support patient efforts to maintain health and lifestyle regimens and comply with prescribed treatment plans. For more information about MEMOTEXT visit

SOURCE MEMOTEXT Personalized Adherence Solutions
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pennsylvania Patient Safety Authority Launches New Website and Design With New Tagline Analyzing, Educating and Collaborating for Patient Safety
2. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
3. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
4. Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix
5. YMCA of the USA Expands Healthy Communities Initiatives With $6.8 Million Grant from the Robert Wood Johnson Foundation
6. Johnson Matthey Medical Announces Expansion
7. Posit Science Invited to Speak at Johns Hopkins University About Cutting Edge Cognitive Training Interventions
8. Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity
9. Video: Magic Johnson Foundation and Abbott Call for Greater Prevention, Testing and Treatment on World AIDS Day
10. Johns Hopkins and Makerere University to collaborate on African health education initiative
11. Johnson & Johnson Begins Tender Offer to Acquire Omrix
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... World Patent Marketing , ... a container patent that allows for easier packing and organizing of items into one ... $90 billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing and ...
(Date:12/1/2015)... ... December 01, 2015 , ... Integrated Rental Services ... Jordan Industries International, LLC (“JII”). , With support from JII, Integrated Rental is ... to hospitals, surgery centers, clinics, research labs and medical facilities across the United ...
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ compensation ... utilization of hospital and nonhospital care, according to a recent study by the Workers ... 16th Edition , found medical payments per claim with more than seven days of ...
(Date:12/1/2015)... ... ... It’s official: Tattoo taboo is a thing of the past. One in five ... one in three aged 18 to 25 is inked). As tattoos transition to mainstream ... fact, RealSelf , the world’s largest community for learning and sharing information about ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 ... today announced that its Chief Executive Officer, ... the Oppenheimer Annual Healthcare Conference in New ... in the conference through a webcast on ... , --> ...
(Date:12/1/2015)... Pharma Tech Outlook recently conducted a comprehensive ... Management Solution Providers - 2015 .  After careful consideration ... CIOs, VCs, analysts, and the Pharma Tech Outlook editorial ... 10 clinical data management solution providers (check out the ... 36 respectively). --> ...
(Date:12/1/2015)... , 1 de diciembre de 2015 /PRNewswire/ ... para cuchillas de precisión, develó hoy un ... identidad de marca. El nuevo logo destaca ... y la ingeniería de productos con cuchillas ... ...
Breaking Medicine Technology: